Core Insights - Vor Bio has appointed Dr. Navid Z. Khan as Chief Medical Affairs Officer, bringing over two decades of experience in medical affairs, commercial, and R&D functions [1][2] - Dr. Khan has overseen more than 40 development programs and successfully guided seven product launches in neurology and immunology [2] - The company is focused on advancing telitacicept, a novel dual-target fusion protein, through Phase 3 clinical development to address serious autoantibody-driven conditions [5] Company Overview - Vor Bio is a clinical-stage biotechnology company dedicated to transforming the treatment of autoimmune diseases [5] - The company aims to ensure strong scientific exchange, evidence generation, and meaningful engagement with patient and physician communities worldwide [3] Leadership Background - Dr. Khan previously held senior leadership positions at argenx, Akouos Inc., and Sarepta Therapeutics, where he played a pivotal role in launching therapies for Duchenne muscular dystrophy [2][3] - He earned his Ph.D. in Biomedical Engineering and Biotechnology and holds a B.S. in Biochemistry and Molecular Biology [4]